Details

Autor(en) / Beteiligte

• Schatzberg, Alan F.

Titel

An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression

Ist Teil von

• The American journal of psychiatry, 2022-12, Vol.179 (12), p.890-891

Ort / Verlag

United States: American Psychiatric Association

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Schatzberg discusses the report by Price et al that automated self-associated training (ASAT) was statistically better than sham treatment in maintaining the antidepressant response to an intravenous ketamine infusion. Ketamine given intravenously has been reported to produce rapid antidepressant and dissociative responses but to generally lose its antidepressant effect over a period of a week. They assessed the maintenance of the blind and noted that the ketamine phase expectedly appeared to violate the blind, whereas the ASAT phase did not. The study is innovative, well powered, and elegant in design and implementation and appears to be a potentially major step forward in follow-up treatment after acute intravenous infusions of ketamine.